Klotho Neurosciences, Inc. Stock Price, News & Analysis

Klotho Neurosciences (NASDAQ: KLTO) announced advancement in manufacturing and process development for KLTO-202, its investigational gene therapy treatment for amyotrophic lateral sclerosis (ALS). The company has licensed a unique RNA splice variant of the human alpha-Klotho gene from the Autonomous University of Barcelona for developing advanced gene therapies.

The company's research has demonstrated that overexpression of secreted alpha-Klotho (s-KL) using gene therapy has shown positive therapeutic outcomes in multiple animal studies, including mouse and non-human primate models. The timeline for development indicates approximately 8 months for manufacturing and 4-6 months for regulatory processes, with Phase I/II clinical trials expected to begin by Q3 2026.

KLTO plans to collaborate with contract research organizations (CROs) to manage manufacturing and clinical trials, maintaining operational efficiency without significant staff expansion. The company aims to use an AAV vector to deliver the s-KL gene directly to motor neurons affected by ALS, a disease that typically leads to paralysis and death within 2-3 years of diagnosis.

Klotho Neurosciences (NASDAQ: KLTO) has announced a partnership with the Okinawa Research Center for Longevity Science (ORCLS) to study tissue levels of the human Klotho gene and protein in Okinawa's centenarian population. The research focuses on understanding how the alpha-Klotho protein may contribute to healthy longevity and lifespan.

The collaboration will analyze blood samples from ORCLS's extensive centenarian study database to investigate the role of Klotho protein in promoting longevity and reducing risks of neurodegenerative diseases. KLTO's preliminary data suggests that maintaining optimum blood levels of Klotho protein in later life correlates with longevity, while lower levels are associated with premature aging and neurological disorders.

The company's patent-protected secreted s-KL protein isoform shows promise for treating conditions like ALS, Alzheimer's, Parkinson's, and other age-related disorders including sarcopenia, osteoporosis, diabetes, and cardiovascular conditions.

Klotho Neurosciences (NASDAQ: KLTO) has announced the mutual termination of its Share Exchange Agreement with SkyBell Technologies, originally signed on March 26, 2025. The termination, formalized on June 13, 2025, prevents substantial shareholder dilution that would have resulted in SkyBell owning 90% of KLTO. The decision allows Klotho to maintain its strategic focus on developing therapeutic and longevity programs, particularly targeting neurodegenerative and age-related diseases. CEO Dr. Joseph Sinkule emphasized the company's commitment to developing anti-aging gene and biologic therapies aimed at slowing the aging process and reducing mortality from age-related organ failure. The termination agreement includes no liability for either party.

Klotho Neurosciences (NASDAQ: KLTO) has successfully raised over $11 million through the exercise of existing warrants by investors over a ten-day period, with Chardan Capital Markets serving as the exclusive financial advisor. The biogenetics company has strategically utilized $3.1 million of the raised funds to fully extinguish all outstanding debt, achieving a debt-free balance sheet. This financial restructuring has positioned KLTO to exceed the stockholders' equity thresholds required for maintaining NASDAQ listing compliance, addressing a critical regulatory requirement.

Klotho Neurosciences (NASDAQ: KLTO) has announced breakthrough findings in longevity research centered on the Klotho gene. The company has secured exclusive worldwide licenses for s-KL protein technology, building on Professor Makoto Kuro-O's 1997 discovery linking Klotho blood levels to mammalian lifespan. Recent studies published in Molecular Therapy demonstrated that genetic overexpression of Klotho increased mouse lifespan by 30-40%, while the secreted form (s-KL) showed a 20% lifespan increase. The research revealed s-KL's potential in addressing age-related conditions including cognitive decline, neuroinflammation, sarcopenia, and osteoporosis. KLTO plans to develop s-KL treatments focusing on neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's, supported by patents in the USA, Europe, and China.

Klotho Neurosciences (NASDAQ: KLTO), a biotechnology company developing cell and gene therapies for ALS, Alzheimer's, and Parkinson's disease, will present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco. The presentation is scheduled for January 14, 2025, at 3:00 PM PT at the Hilton San Francisco Union Square.

CEO Dr. Joseph Sinkule will discuss the company's work with the secreted form of the Klotho anti-aging gene ('s-KL'), their patent-protected development platform. The company aims to increase awareness of this 'master gene' and its potential role in treating neurodegenerative diseases. They are progressing toward clinical trials for ALS and seeking development partnerships for Alzheimer's and Parkinson's treatments.

KLTO has secured exclusive worldwide licenses from UAB and ICREA in Spain, with patents issued in the USA, Europe, and China for their therapeutic approach using s-KL to treat cognitive and behavioral impairments.

Klotho Neurosciences (NASDAQ: KLTO) has appointed Dr. Merit Cudkowicz to its Scientific Advisory Board. Dr. Cudkowicz is the Chair of Neurology at Massachusetts General Hospital, Director of the Sean M. Healey & AMG Center for ALS, and Julieanne Dorn Professor of Neurology at Harvard Medical School. She is a member of the National Academy of Medicine and co-director of the Northeast ALS Consortium, overseeing 150+ clinical sites in the US and Canada.

The company, focused on developing cell and gene therapies for ALS, Alzheimer's, and Parkinson's disease, aims to leverage Dr. Cudkowicz's expertise in clinical trial design and execution. Their approach centers on a patent-protected product candidate expressing the Klotho gene transcribed protein called 's-KL' or 'secreted Klotho' for ALS treatment.

Klotho Neurosciences (NASDAQ: KLTO) has appointed Riad El-Dada, former US President of Merck, to its Board of Directors. During his tenure at Merck, El-Dada managed over $12 billion in revenue across multiple therapeutic areas and served as Managing Director for Australia and New Zealand operations. His experience includes product development, commercialization, strategic partnerships, and policy engagement through the Healthcare Leadership Council. The appointment aims to strengthen the company's development of S-KL, a patent-protected Klotho gene therapy targeting ALS, Alzheimer's, and Parkinson's diseases.

Klotho Neurosciences (NASDAQ: KLTO) announces the appointment of Dr. Makoto Kuro-o to its Scientific Advisory Board. Dr. Kuro-o is renowned for discovering the Klotho gene, known as the 'anti-aging gene,' during his research at the National Institute of Neuroscience in Tokyo. His research showed that mice lacking the Klotho gene aged faster, while those overexpressing it lived longer. The company is developing a patent-protected secreted form of Klotho (s-KL) for treating neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's disease.